The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation

Immunological Reviews

Volumn 157, Issue , 1997, Pages 167-176

  Murphy, William J ^a   Longo, Dan L ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER RECURRENCE; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; LEUKEMIA; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0030797821     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00981.x     Document Type: Review

References (83)

1. Busca A, Amoroso A, Miniero R. Recent advances in bone marrow transplantation from unrelated volunteer donors. Hematology 1996;1:3-9.
2. Storb R. Bone marrow transplantation. Transpl Proc 1995;27:2649-2652.
3. Saarinen UM, Hovi L, Juvonen E, Riikonen P, Mottonen M, Makipernaa A. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children. Med Pediatr Oncol 1996;26:380-386.
4. DeWitte T, et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992;79:1359-1365.
5. Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991;77:2561-2568.
6. Attal M, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995;86:1619-1628.
7. Raspadori D, et al. Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Ann Hematol 1995;71:175-179.
8. Robinson N, et al. Phase I trial of interleukin-2 after unmodified HLA-matched-sibling bone marrow transplantation for children with acute leukemia. Blood 1996;87:1249-1254.
9. Favrot MC, et al. Systemic interleukin-2 therapy in children with progressive neuroblasioma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 1989;4:499-503.
10. Biaise D, et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990;76:1092-1097.
11. Porter DL, Antin JH. Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Leuk Lymphoma 1995;17:3-4.
12. Collins RH, et al. Transfusion of donor huffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Transfusion 1995;35:891-898.
13. Tsuzuki M, Maruyama F, Kojima H, Ezaki K, Hirano M. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;16:487-489.
14. Walter EA, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
15. Kwak LW, Campbell MJ, Zelenetz AD, Levy R. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood 1991;78:2768-2772.
16. Kwak LW, et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995;345:1016-1020.
17. Drobyski WR, Roth MS, Thibodeau SN, Gottschall JL. Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992;10:301-304.
18. Clark RE, Pender N. Transplantation of T-lymphocyte depleted marrow with an addback of T cells. Hematol Oncol 1995;13:219-224.
19. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-vs-host disease while preserving the graft-vs-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 1990;87:5633-5637.
20. - cell population. J Immunol 1992;148:3746-3752.
21. Sykes M, Pearson DA, Szot GL. IL-2-induced GVHD protection is not inhibited by cyclosporine and is maximal when IL-2 is given over a 25 h period beginning on the day following bone marrow transplantation. Bone Marrow Transplant 1995;15:395-399.
22. Charak BS, Brynes RK, Chogyoji M, Kortes V, Tefft M, Mazumder A. Graft versus leukemia effect after transplantation with interleukin-2-activated bone marrow. Transplantation 1993;56:31-37.
23. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995;86:2429-2438.
24. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymhocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422-4429.
25. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995;155:585-593.
26. + lymphoid engraftment. J Immunol 1994;152:1004-1013.
27. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995;85:842-851.
28. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J Immunol 1995;154:2687-2696.
29. Blazar BR, Taylor PA, Panokaltsis-Mortari A, Gray GS, Vallera DA. Co-blockade of the LFA-1: ICAM and CD28/B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully MHC disparate donor grafts. Blood 1995;85:2607-2618.
30. Hakim FT, Cepeda R, Gray GS, June CH, Abe R. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. J Immunol 1995;155:1757-1766.
31. + T cells. J Immunol 1996;157:3250-3259.
32. Durie FH, et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 1994;94:1333-1338.
33. Bennett M. Biology and genetics of hybrid resistance. Adv Immunol 1987;41:333-445.
34. 1 hybrid mice. J Exp Med 1971;134:1513-1528.
35. Yu YY, Kumar V, Bennett M. Murine natural killer cells and marrow graft rejection. Annu Rev Immunol 1992;10:189-213.
36. Murphy WJ, Reynolds CW, Tiberghien P, Longo DL. Natural killer cells and bone marrow transplantation. J Natl Cancer Inst 1993;85:1475-1482.
37. Bukowski JF, et al. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med 1985;161:40-52.
38. Cudkowicz G, Hochman PS. Do natural killer cells engage in regulated reaction against self to ensure homeostasis? Immunol Rev 1979;44:13-41.
39. Trinchieri G, Scott, P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994;15:460-463.
40. Trinchieri G. Biology and natural killer cells. Adv Immunol 1989;47:187-376.
41. Murphy WJ, Keller JR, Harrison, CL, Young HA, Longo DL. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 1991;80:670-677.
42. Kasahara T, et al. Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin-2, interferon and colony stimulating factor. J Immunol 1983;131:2379-2385.
43. Levitt LJ, et al. Production of granulocyte/ macrophage-colony-stimulating factor by human natural killer cells: modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. J Clin Invest 1991;88:67-75.
44. Baker M, Podack ER, Levy R. Perforin and Fas mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol Blood Marrow Transplant 1995;1: 69-73.
45. Aguila HL, Weissman IL. Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells. Blood 1996;87:1225-1231.
46. Tiberghien P, et al. Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery. Blood 1990;76:1419-1430.
47. Rolstad B, Benestad HB. Spontaneous alloreactivity of natural killer (NK) and lymphokine-activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis. Immunology 1991;74:86-93.
48. Murphy WJ, Longo DL. Hematopoietic growth-promoting effects of natural killer cells in mice in response to in vivo administration of human interleukin-2. J Natl Cancer Inst 1992;84:1195-1200.
49. Murphy WJ, Bennett M, Kumar V, Longo DL. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol 1992;148:2953-2960.
50. Siefer AK, Longo DL, Harrison CL, Reynolds CW, Murphy WJ. Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice. Blood 1993;82:2577-2584.
51. Silla LM, Whiteside TL, Ball ED. The role of natural killer cells in the treatment of chronic myeloid leukemia. J Hematother 1995;4:269-279.
52. + NK cells are responsible for mediating the rejection of H-2b bone marrow allografts in mice. Int Immunol 1996;8:1833-1839.
53. Murphy WJ, Longo DL. NK cells in the regulation of hematopoiesis. Methods 1996;39:344-351.
54. Yokoyama WM, Seaman WE. The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. Annu Rev Immunol 1993;11:613-635.
55. Moretta L, et al. Allorecognition by NK cells: nonself or no self? Immunol Today 1992;13:300-306.
56. Wang LL, Mehta IK, LeBlanc PA, Yokoyama WM. Mouse natural killer cells express gp49B1, a structural homologue of human killer inhibitory receptors. J Immunol 1997;158:13-17.
57. Mingari MC, et al. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int Immunol 1995;7:697-703.
58. Yu YLL, George T, Dorfman JR, Roland J, Kumar V, Bennett M. The role of Ly-49A and 5E6 (Ly-49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 1996;4:67-72.
59. Lanier LL, Spits H, Philips JH. The developmental relationship between NK cells and T cells. Immunol Today 1992;13:392-395.
60. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med 1993;178:703-712.
61. Murphy WJ, et al. An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells. J Immunol 1990;144:3305-3311.
62. Charley MR, et al. Prevention of lethal, minor-determinate graft-host disease in mice by the in vivo administration of anti-asialo GM. J Immunol 1983;131:2101-2103.
63. + cells of donor origin. Transplantation 1988;45:586-590.
64. Ghayur T, Seemayer TA, Lapp WS. Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction: relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations. Transplantation 1987;44:254-260.
65. Dokhelar MC, et al. Natural killer cell activity in human bone marrow recipients: early reappearance of peripheral natural killer activity in graft-versus-host disease. Transplantation 1981;31:61-65.
66. Azuma E, Kaplan J. Role of lymphokine-activated killer (LAK) cells as mediators of veto and natural suppression. J Immunol 1988;141:2601-2606.
67. Yamamoto H, Hirayama M, Genyea C, Kaplan J. TGF-β 1 mediates natural suppressor activity of IL-2-activated lymphocytes. J Immunol 1994;152:3842-3847.
68. Ferrera JL, Deeg, HJ. Graft-versus-host disease. New Engl J Med 1991;324:667-672.
69. Murphy WJ, Kumar V, Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med 1987;165:1212-1217.
70. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994;83;1323-1328.
71. Habu S, et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 1981;127:34-38.
72. Okunewick JP, Kociban DL, Machen LL, Buffo MJ. Evidence for a possible role of Asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia. Bone Marrow Transplant 1995;16:451-456.
73. Weiss L, Reich S, Slavin S. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia. Bone Marrow Transplant 1995;16:457-461.
74. Zeis M, et al. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995;59:1734-1736.
75. Glass B, et al. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol 1996;93:412-420.
76. Hauch M, et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990;75:2250-2262.
77. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cell. Immunol Today 1993;14:335-338.
78. Puzanov IJ, Bennett M, Kumar V. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J Immunol 1996;157:4282-4285.
79. Murphy WJ, Rui H, Longo DL. Effects of meuroendocrine hormones on immune development and function. Life Sci 1995;57:1-14.
80. Murphy WJ, Durum SK, Anver MR, Longo DL. Immunologic and hematologic effects of neuroendocrine hormones. J Immunol 1992;148:3799-3805.
81. Murphy WJ, Tsarfaty G, Longo DL. Growth hormone exerts hematologic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Blood 1992;80:1443-1447.
82. Murphy WJ, Durum SK, Longo DL. Role of neuroendocrine hormones in murine T cell development. J Immunol 1992;149:3851-3856.
83. Lister J, et al. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1995;1:607-613.